Brief: Theranexus Announces Clinical Results Of Phase IB Study Of Drug Candidate THN201

Thx Pharma SA

15/01/2020 18:08

Jan 15 (Reuters) - Theranexus SA  ALTHX.PA :
    * THERANEXUS ANNOUNCES CLINICAL RESULTS OF PHASE IB STUDY
DEMONSTRATING THE EXTENDED PHARMACOLOGICAL PROFILE OF ITS DRUG
CANDIDATE THN201 COMPARED TO DONEPEZIL
    * IMPROVED SPEED OF MEMORY
    * SIMILAR PROFILE WITH RESPECT TO OTHER PHARMACOLOGICAL,
PHARMACOKINETIC AND TOLERANCE ENDPOINTS
    * SIGNIFICANT INCREASE IN EEG POWER IN THE GAMMA BAND
RELATED TO
COGNITIVE ACTIVITY
    * DATA ON SAFETY ENDPOINTS DEMONSTRATE THAT THN201 DISPLAYS
EXCELLENT TOLERABILITY SIMILAR TO THAT OF DONEPEZIL
    * DATA REGARDING THE OTHER MEASURED PHARMACOLOGICAL
ENDPOINTS
REVEAL THAT THE PROFILES OF THN201 AND DONEPEZIL ARE SIMILAR

Source text : https://bit.ly/2FRBVGX
Further company coverage:  ALTHX.PA 

 (Gdansk Newsroom)
 ((gdansk.newsroom@thomsonreuters.com; +48 58 7785110;))